CLINICAL DATA

SEVERE ASTHMA PATIENTS CAN HAVE MULTIPLE TRIGGERS & DRIVERS AND CAN VARY IN THEIR CLINICAL PRESENTATIONS1-4

Not an actual patient.
For illustrative purposes only. Results may vary.

TEZSPIRE showed significant exacerbation reductions vs placebo (PATHWAY 71%, NAVIGATOR 56%, P<0.001; primary endpoint) and a 230 mL improvement in lung function vs baseline (NAVIGATOR; secondary endpoint).5*

*PATHWAY AAER: TEZSPIRE + SOC 0.20 (n=137) vs placebo + SOC 0.72 (n=138); RR: 0.29 (95% CI: 0.16-0.51); NAVIGATOR AAER: TEZSPIRE + SOC 0.93 (n=528) vs placebo + SOC 2.10 (n=531); RR: 0.44 (95% CI: 0.37-0.53).5

AAER=annualized asthma exacerbation rate; CI=confidence interval; RR=rate ratio; SOC=standard of care.

Common asthma triggers include2:

GrassesGrasses
Dog danderDog dander
DustDust
Viral infectionViral infection
Cold airCold air
Air pollutionAir pollution
MoldMold

POST HOC ANALYSIS

EOS WITH POSITIVE AEROALLERGEN TESTING:

150-299 cells/μL6*

≥300 cells/μL7*

>450 cells/μL6*

IgE:

500 IU/mL

>300 IU/mL

<100 IU/mL

Post hoc pooled analysis

Reduction in exacerbations

data from baseline
seventy-seven

TEZSPIRE + SOC (n=137) Baseline 2.60 vs EOT 0.606†‡

seventy-nine

TEZSPIRE + SOC (n=181) Baseline 2.96 vs EOT 0.637†§

seventy-nine

TEZSPIRE + SOC (n=98) Baseline 2.96 vs EOT 0.526†II

Results are descriptive only. Definitive conclusions cannot be made.

See patient profiles

*Allergic status is defined by a serum lgE result specific to any perennial aeroallergen in the FEIA panel.6,7

†Baseline is defined as the mean number of exacerbations per patient in the 12 months prior to study enrollment. EOT is defined as crude exacerbation rate (total number of exacerbations that occurred over the total time at risk).6,7

‡Post hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 2.42 and EOT 1.28 (n=132; 47% reduction from baseline).6†

§Post hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 2.94 and EOT 1.88 (n=179; 36% reduction from baseline).7†

IIPost hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 3.10 and EOT 2.20 (n=106; 29% reduction from baseline).6†

EOS=eosinophils; EOT=end of treatment; FEIA=fluorescence enzyme immunoassay; IgE=immunoglobulin E; SOC=standard of care.

EOS WITH POSITIVE AEROALLERGEN TESTING:

150-299 cells/μL6*

≥300 cells/μL7*

>450 cells/μL6*

IgE:

500 IU/mL

>300 IU/mL

<100 IU/mL

Post hoc pooled analysis

Reduction in exacerbations requiring hospitalizations,

urgent care, or ED visits

data from baseline
Ninty six

TEZSPIRE + SOC (n=137) Baseline 0.47 vs EOT 0.026†‡

seventy-nine

TEZSPIRE + SOC (n=181) Baseline 0.44 vs EOT 0.037†§

seventy-nine

TEZSPIRE + SOC (n=98) Baseline 0.38 vs EOT 0.036†II

Results are descriptive only. Definitive conclusions cannot be made.

*Allergic status is defined by a serum lgE result specific to any perennial aeroallergen in the FEIA panel.6,7

†Baseline is defined as the mean number of exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT is defined as crude exacerbation rate (total number of exacerbations related to hospitalization or ER visits that occurred over the total time at risk).6,7

‡Post hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 0.33 and EOT 0.11 (n=132; 67% reduction from baseline).6†

§Post hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 0.47 and EOT 0.23 (n=179; 51% reduction from baseline).7†

IIPost hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 0.56 and EOT 0.29 (n=106; 48% reduction from baseline).6†

ED=emergency department; EOS=eosinophils; EOT=end of treatment; ER=emergency room; FEIA=fluorescence enzyme immunoassay; IgE=immunoglobulin E; SOC=standard of care.

EOS WITH POSITIVE AEROALLERGEN TESTING:

150-299 cells/μL6*

≥300 cells/μL7*

>450 cells/μL6*

IgE:

500 IU/mL

>300 IU/mL

<100 IU/mL

Post hoc pooled analysis

Improvements in FEV1

data from baseline
Ninty six

TEZSPIRE + SOC (n=134)6†

seventy-nine

TEZSPIRE + SOC (n=171)7‡

seventy-nine

TEZSPIRE + SOC (n=98)6§

Results are descriptive only. Definitive conclusions cannot be made.

LUNG FUNCTION IMPROVEMENT THAT LASTS SO PATIENTS CAN BREATHE EASIER WITH TEZSPIRE5,6,8

Lung-graph

Results are descriptive only. Definitive conclusions cannot be made.

*Allergic status is defined by a serum lgE result specific to any perennial aeroallergen in the FEIA panel.6,7

†Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline placebo + SOC FEV1 100 mL (n=132); LS mean difference between groups 20 mL (95% CI: -70 to 120).6

‡Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline placebo + SOC FEV1 160 mL (n=165); LS mean difference between groups 210 mL (95% CI: 120-290).7

§Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline placebo + SOC FEV1 200 mL (n=106); LS mean difference between groups 240 mL (95% CI: 130-350).6

CI=confidence interval; EOS=eosinophils; FEIA=fluorescence enzyme immunoassay; FEV1=forced expiratory volume in 1 second; IgE=immunoglobulin E; LS=least-squares; RR=rate ratio; SOC=standard of care.

POST HOC ANALYSIS

EOS WITH POSITIVE AEROALLERGEN TESTING:

150-299 cells/μL6*

≥300 cells/μL7*

>450 cells/μL6*

IgE:

500 IU/mL

>300 IU/mL

<100 IU/mL

Post hoc pooled analysis

Reduction in exacerbations

data from baseline
seventy-seven

TEZSPIRE + SOC (n=137) Baseline 2.60 vs EOT 0.606†‡

seventy-nine

TEZSPIRE + SOC (n=181) Baseline 2.96 vs EOT 0.637†§

seventy-nine

TEZSPIRE + SOC (n=98) Baseline 2.96 vs EOT 0.526†II

Results are descriptive only. Definitive conclusions cannot be made.

See patient profiles

*Allergic status is defined by a serum lgE result specific to any perennial aeroallergen in the FEIA panel.6,7

†Baseline is defined as the mean number of exacerbations per patient in the 12 months prior to study enrollment. EOT is defined as crude exacerbation rate (total number of exacerbations that occurred over the total time at risk).6,7

‡Post hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 2.42 and EOT 1.28 (n=132; 47% reduction from baseline).6†

§Post hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 2.94 and EOT 1.88 (n=179; 36% reduction from baseline).7†

IIPost hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 3.10 and EOT 2.20 (n=106; 29% reduction from baseline).6†

EOS=eosinophils; EOT=end of treatment; FEIA=fluorescence enzyme immunoassay; IgE=immunoglobulin E; SOC=standard of care.

EOS WITH POSITIVE AEROALLERGEN TESTING:

150-299 cells/μL6*

≥300 cells/μL7*

>450 cells/μL6*

IgE:

500 IU/mL

>300 IU/mL

<100 IU/mL

Post hoc pooled analysis

Reduction in exacerbations requiring hospitalizations,

urgent care, or ED visits

data from baseline
Ninty six

TEZSPIRE + SOC (n=137) Baseline 0.47 vs EOT 0.026†‡

seventy-nine

TEZSPIRE + SOC (n=181) Baseline 0.44 vs EOT 0.037†§

seventy-nine

TEZSPIRE + SOC (n=98) Baseline 0.38 vs EOT 0.036†II

Results are descriptive only. Definitive conclusions cannot be made.

*Allergic status is defined by a serum lgE result specific to any perennial aeroallergen in the FEIA panel.6,7

†Baseline is defined as the mean number of exacerbations related to hospitalization or ER visits per patient in the 12 months prior to study enrollment. EOT is defined as crude exacerbation rate (total number of exacerbations related to hospitalization or ER visits that occurred over the total time at risk).6,7

‡Post hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 0.33 and EOT 0.11 (n=132; 67% reduction from baseline).6†

§Post hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 0.47 and EOT 0.23 (n=179; 51% reduction from baseline).7†

IIPost hoc analysis of pooled PATHWAY and NAVIGATOR data. Placebo + SOC baseline 0.56 and EOT 0.29 (n=106; 48% reduction from baseline).6†

ED=emergency department; EOS=eosinophils; EOT=end of treatment; ER=emergency room; FEIA=fluorescence enzyme immunoassay; IgE=immunoglobulin E; SOC=standard of care.

EOS WITH POSITIVE AEROALLERGEN TESTING:

150-299 cells/μL6*

≥300 cells/μL7*

>450 cells/μL6*

IgE:

500 IU/mL

>300 IU/mL

<100 IU/mL

Post hoc pooled analysis

Improvements in FEV1

data from baseline
Ninty six

TEZSPIRE + SOC (n=134)6†

seventy-nine

TEZSPIRE + SOC (n=171)7‡

seventy-nine

TEZSPIRE + SOC (n=98)6§

Results are descriptive only. Definitive conclusions cannot be made.

LUNG FUNCTION IMPROVEMENT THAT LASTS SO PATIENTS CAN BREATHE EASIER WITH TEZSPIRE5,6,8

Lung-graph

Results are descriptive only. Definitive conclusions cannot be made.

*Allergic status is defined by a serum lgE result specific to any perennial aeroallergen in the FEIA panel.6,7

†Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline placebo + SOC FEV1 100 mL (n=132); LS mean difference between groups 20 mL (95% CI: -70 to 120).6

‡Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline placebo + SOC FEV1 160 mL (n=165); LS mean difference between groups 210 mL (95% CI: 120-290).7

§Post hoc analysis of pooled PATHWAY and NAVIGATOR data. LS mean change from baseline placebo + SOC FEV1 200 mL (n=106); LS mean difference between groups 240 mL (95% CI: 130-350).6

CI=confidence interval; EOS=eosinophils; FEIA=fluorescence enzyme immunoassay; FEV1=forced expiratory volume in 1 second; IgE=immunoglobulin E; LS=least-squares; RR=rate ratio; SOC=standard of care.

border-line

*PATHWAY AAER: TEZSPIRE + SOC 0.20 (n=137) vs placebo + SOC 0.72 (n=138); RR: 0.29 (95% Cl: 0.16-0.51); NAVIGATOR AAER: TEZSPIRE + SOC 0.93 (n=528) vs placebo + SOC 2.10 (n=531); RR: 0.44 (95% Cl: 0.37-0.53).1

AAER=annualized asthma exacerbation rate; CI=confidence interval, RR=rate ratio; SOC=standard of care.

TEZSPIRE study data across key trigger types and seasons9-11

Exacerbation reduction data

By key trigger type10*
Allergen exposure

Allergen exposure

Infection

Infection

other

Other (eg, weather, fumes,

stress, and air pollution)

Unkonwn

Unknown

71%
41%
47%
62%
reduction
TEZSPIRE + SOC (n=528); placebo + SOC (n=531)Post hoc analysis of the NAVIGATOR clinical trial.
By season11†
Spring

Spring(April to June)

Summer

Summer(July to September)

Fall

Fall(October to December)

winter

Winter(January to March)

80%
82%
67%
64%
reduction
TEZSPIRE + SOC (n=137); placebo + SOC (n=138)Post hoc analysis of the PATHWAY clinical trial.
Results are descriptive only. Definitive conclusions cannot be made.

*95% confidence intervals for exacerbation rates for placebo, TEZSPIRE, and percent reduction between groups. Allergen exposure: placebo 0.14 (0.10-0.20), TEZSPIRE 0.04 (0.02-0.07), reduction 71% (47-84). Infection: placebo 0.49 (0.41-0.57), TEZSPIRE 0.28 (0.23-0.35), reduction 41% (24-55). Other: placebo 0.27 (0.20-0.36), TEZSPIRE 0.14 (0.10-0.20), reduction 47% (20-65). Unknown: placebo 1.03 (0.86-1.24), TEZSPIRE 0.40 (0.32-0.49), reduction 62% (49-71). Analyses were not performed on exacerbation reductions to individual triggers within the “other” category.10

†95% confidence intervals for exacerbation rates for placebo, TEZSPIRE, and percent reduction between groups. Spring: placebo 0.62 (0.39-0.95), TEZSPIRE 0.13 (0.03-0.33), reduction 80% (41-93). Summer: placebo 0.67 (0.43-1.01), TEZSPIRE 0.12 (0.03-0.32), reduction 82% (48-94). Fall: placebo 0.73 (0.47-1.08), TEZSPIRE 0.25 (0.11-0.49), reduction 67% (21-86). Winter: placebo 0.87 (0.58-1.24), TEZSPIRE 0.32 (0.15-0.58), reduction 64% (22-83). Data from patients in the southern hemisphere were transformed to align with equivalent seasonal time periods in the northern hemisphere by shifting the data by 6 months.11

SOC=standard of care.

TEZSPIRE Clinical Data Tool Tablet

EXPLORE DATA IN PATIENTS WITH MULTIPLE DRIVERS OF DISEASE

TRY OUR CLINICAL DATA TOOL
 

Back

FAQs

Next

Clinical Trial Designs

Important Safety Information

Collapse

CONTRAINDICATIONS

Known hypersensitivity to tezepelumab-ekko or excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions were observed in the clinical trials (eg, rash and allergic conjunctivitis) following the administration of TEZSPIRE. Postmarketing cases of anaphylaxis have been reported. These reactions can occur within hours of administration, but in some instances have a delayed onset (i.e., days). In the event of a hypersensitivity reaction, consider the benefits and risks for the individual patient to determine whether to continue or discontinue treatment with TEZSPIRE.

Acute Asthma Symptoms or Deteriorating Disease

TEZSPIRE should not be used to treat acute asthma symptoms, acute exacerbations, acute bronchospasm, or status asthmaticus.

Abrupt Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with TEZSPIRE. Reductions in corticosteroid dose, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infection

It is unknown if TEZSPIRE will influence a patient’s response against helminth infections. Treat patients with pre-existing helminth infections before initiating therapy with TEZSPIRE. If patients become infected while receiving TEZSPIRE and do not respond to anti-helminth treatment, discontinue TEZSPIRE until infection resolves.

Live Attenuated Vaccines

The concomitant use of TEZSPIRE and live attenuated vaccines has not been evaluated. The use of live attenuated vaccines should be avoided in patients receiving TEZSPIRE.

ADVERSE REACTIONS

The most common adverse reactions (incidence ≥ 3%) are:

  • Asthma: pharyngitis, arthralgia, and back pain.
  • Chronic rhinosinusitis with nasal polyps: nasopharyngitis, upper respiratory tract infection, epistaxis, pharyngitis, back pain, influenza, injection site reaction and arthralgia

USE IN SPECIFIC POPULATIONS

There are no available data on TEZSPIRE use in pregnant women to evaluate for any drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Placental transfer of monoclonal antibodies such as tezepelumab-ekko is greater during the third trimester of pregnancy; therefore, potential effects on a fetus are likely to be greater during the third trimester of pregnancy.

INDICATION

TEZSPIRE is indicated for:

  • the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus
  • the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP)

Please see full Prescribing Information, including
Patient Information and Instructions for Use.

You may report side effects related to AstraZeneca products Opens new window. Opens new window

Important Safety Information

 +

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2.  Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19)(suppl):1-60.

Reference: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 4. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 3. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 4. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 5. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 6. Data on File. US-105253, AstraZeneca Pharmaceuticals LP. 7. Data on File. US-98796, AstraZeneca Pharmaceuticals LP.

Reference: 1. Data on File. US-105253, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 3. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 4. Data on File. US-91518, AstraZeneca Pharmaceuticals LP.

Reference: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025.

References: 1. Price D, Dale P, Elder E, Chapman KR. Types, frequency and impact of asthma triggers on patients’ lives: a quantitative study in five European countries. J Asthma. 2014;51(2):127-135. 2. Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. J Asthma Allergy. 2017;10:47-56. 3. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 4. Porsbjerg CM, Sverrild A, Lloyd CM, et al. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J. 2020;56(5):2000260. 5. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 6. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 7. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 8. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236.

References: 1. Data on File. REF-134673, AstraZeneca Pharmaceuticals LP. 2. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Data on File. REF-134414, AstraZeneca Pharmaceuticals LP. 5. Laidlaw TM, Menzies-Gow A, Caveney S, et al. Tezepelumab efficacy in patients with severe, uncontrolled asthma with comorbid nasal polyps in NAVIGATOR. J Asthma Allergy. 2023;16:915-932. 6. Data on File. REF-263922, AstraZeneca Pharmaceuticals LP. 7. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(suppl):1-60.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Gauvreau GM, Sehmi R, Ambrose CS, et al. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 4. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 5. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 6. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 7. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 8. Dunican EM, Elicker BM, Gierada DS, et al. Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. J Clin Invest. 2018;128(3):997-1009. 9. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 10. Nordenmark LH, Hellqvist Å, Emson C, et al. Tezepelumab and mucus plugs in patients with moderate-to-severe asthma. NEJM Evid. 2023;2(10):1-10. 11. Data on File. REF-176078, AstraZeneca Pharmaceuticals LP. 12. Data on File. REF-188753, AstraZeneca Pharmaceuticals LP. 13. Data on File. REF-148129, AstraZeneca Pharmaceuticals LP.

References: 1. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 2. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 4. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7. 5. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 6. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 7. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP. 8. Data on File. REF-134414, AstraZeneca Pharmaceuticals LP. 9. Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. J Asthma Allergy. 2017;10:47-56. 10. Data on File. REF-224439, AstraZeneca Pharmaceuticals LP. 11. Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: a post hoc analysis of the PATHWAY phase 2b study. J Asthma Allergy. 2021;14:1-11.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(10):936-946. 3. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 4. Corren J, Parnes JR, Wang L, et al. Appendix to: Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017;377(suppl):1-54. 5. Menzies-Gow A, Corren J, Bourdin A, et al. Appendix to: Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(suppl):1-60. 6. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 7. Data on File. REF-134673, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 3. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP.

References: 1. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7. 2. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 3. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 4. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 5. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 6. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 7. Diver S, Khalfaoui L, Emson C, et al; CASCADE study investigators. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(11):1299-1312. 8. Data on File. REF-148129, AstraZeneca Pharmaceuticals LP. 9. Data on File. REF-204597, AstraZeneca Pharmaceuticals LP. 10. Data on File. REF-181622, AstraZeneca Pharmaceuticals LP. 11. Data on File. REF-134414, AstraZeneca Pharmaceuticals LP. 12. Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800-1809. 13. Data on File. REF-224439, AstraZeneca Pharmaceuticals LP. 14. Corren J, Karpefors M, Hellqvist Å, Parnes JR, Colice G. Tezepelumab reduces exacerbations across all seasons in patients with severe, uncontrolled asthma: a post hoc analysis of the PATHWAY phase 2b study. J Asthma Allergy. 2021;14:1-11. 15. Data on File. US-98281, AstraZeneca Pharmaceuticals LP.

References: 1. Porsbjerg CM, Sverrild A, Lloyd CM, et al. Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. Eur Respir J. 2020;56(5):2000260. 2. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 3. Panettieri R Jr, Lugogo N, Corren J, Ambrose CS. Tezepelumab for severe asthma: one drug targeting multiple disease pathways and patient types. J Asthma Allergy. 2024;17:219-236. 4. Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13-24. 5. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 6. Brace yourselves: the biggest week for asthma attacks is coming. Asthma and Allergy Foundation of America. Published August 25, 2022. Accessed August 5, 2025. https://community.aafa.org/blog/September-Asthma-Peak-brace-yourselves-the-biggest-week-for-asthma-attacks-is-coming. 7. Protect your child against the September epidemic. National Jewish Health. Accessed August 5, 2025. https://www.nationaljewish.org/conditions/health-information/multimedia/living-with-asthma/protect-your-child-against-the-september-epidemic. 8. Sheehan WJ, Patel SJ, Margolis RH, et al. Pediatric asthma exacerbations during the COVID-19 pandemic: absence of the typical fall seasonal spike in Washington, DC. J Allergy Clin Immunol Pract. 2021;9(5):2073-2076. 9. Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. J Asthma Allergy. 2017;10:47-56. 10. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5.

References: 1. van der Veen J, Seys SF, Timmermans M, et al. Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre. Allergy. 2017;72(2):282-290. 2. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 3. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 3. Data on File. US-98796, AstraZeneca Pharmaceuticals LP.

References: 1. TEZSPIRE® (tezepelumab-ekko) [package insert]. Thousand Oaks, CA: Amgen Inc.; and Wilmington, DE: AstraZeneca Pharmaceuticals LP; October 2025. 2. Data on File. REF-292218, AstraZeneca Pharmaceuticals LP. 3. Pfaar O, Han JK, Desrosiers M, et al. Onset of action of tezepelumab in adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps in the phase 3 WAYPOINT study. Presented at: European Rhinologic Society (ERS) 2025 Congress; June 22-25, 2025; Budapest, Hungary. 4. Lipworth BJ, Han JK, Desrosiers M, et al. Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps [Appendix]. N Engl J Med. 2025;392(12):1178-1188. 5. Lipworth BJ, Han JK, Desrosiers M, et al. Tezepelumab in adults with severe chronic rhinosinusitis with nasal polyps. N Engl J Med. 2025;392(12):1178-1188. 6. Chowdhury NI, Mace JC, Bodner TE, et al. Investigating the minimal clinically important difference for SNOT-22 symptom domains in surgically managed chronic rhinosinusitis. Int Forum Allergy Rhinol. 2017;7(12):1149-1155. 7. Data on File. REF-287771, AstraZeneca Pharmaceuticals LP. 8. Data on File. WAYPOINT Clinical study report. Tezepelumab D5242C00001; January 23, 2025.

References: 1. Kato A, Schleimer RP, Bleier BS. Mechanisms and pathogenesis of chronic rhinosinusitis. J Allergy Clin Immunol. 2022;149(5):1491-1503. 2. Peters A, Zhao X, Near AM, et al. Real-world outcomes following biologic initiation in US patients with chronic rhinosinusitis with nasal polyps. Adv Ther. 2025;42(4):1783-1799. 3. Bachert C, Zhang N, Cavaliere C, Weiping W, Gevaert E, Krysko O. Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2020;145(3):725-739. 4. Menzies-Gow A, Wechsler ME, Brightling CE. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option? Respir Res. 2020;21(1):268. 5. Gauvreau GM, Sehmi R, Ambrose CS, Griffiths JM. Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. Expert Opin Ther Targets. 2020;24(8):777-792. 6. Ha J-G, Cho H-J. Unraveling the role of epithelial cells in the development of chronic rhinosinusitis. Int J Mol Sci. 2023;24(18):14229. 7. Chipps BE, Soong W, Panettieri RA Jr, et al. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023;130(6):784-790.e5. 8. Denton E, Price DB, Tran TN, et al. Cluster analysis of inflammatory biomarker expression in the International Severe Asthma Registry. J Allergy Clin Immunol Pract. 2021;9(7):2680-2688.e7. 9. Gautier C, Charpin D. Environmental triggers and avoidance in the management of asthma. J Asthma Allergy. 2017;10:47-56.

This product information is intended for US Healthcare Professionals only.

TEZSPIRE is a registered trademark of Amgen Inc.
and AstraZeneca.
©2026 AstraZeneca. All rights reserved. US-106943; US-110429 Last Updated 7/26US-99228; US-106278; US-106943 Last Updated 3/26